

[¹¹C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy

Luca Passamonti, MD,* Patricia Vázquez Rodríguez, MPhil,* Young T. Hong, PhD, Kieren S.J. Allinson, MD, W. Richard Bevan-Jones, MD, David Williamson, P. Simon Jones, Robert Arnold, Robin J. Borchert, MPhil, Ajenthan Surendranathan, MD, Elijah Mak, PhD, Li Su, PhD, Tim D. Fryer, PhD, Franklin I. Aigbirhio, DPhil, John T. O'Brien, DM,† and James B. Rowe, MD‡

Correspondence

Dr. Passamonti
lp337@medschl.cam.ac.uk

Neurology® 2018;0:1-8. doi:10.1212/WNL.0000000000005610

Abstract

Objective

We tested whether in vivo neuroinflammation relates to the distinctive distributions of pathology in Alzheimer disease (AD) and progressive supranuclear palsy (PSP).

Methods

Sixteen patients with symptomatic AD (including amnesic mild cognitive impairment with amyloid-positive PET scan), 16 patients with PSP–Richardson syndrome, and 13 age-, sex-, and education-matched healthy controls were included in this case-control study. Participants underwent [¹¹C]PK11195 PET scanning, which was used as an in vivo index of neuroinflammation.

Results

[¹¹C]PK11195 binding in the medial temporal lobe and occipital, temporal, and parietal cortices was increased in patients with AD, relative both to patients with PSP and to controls. Compared to controls, patients with PSP showed elevated [¹¹C]PK11195 binding in the thalamus, putamen, and pallidum. [¹¹C]PK11195 binding in the cuneus/precuneus correlated with episodic memory impairment in AD, while [¹¹C]PK11195 binding in the pallidum, midbrain, and pons correlated with disease severity in PSP.

Conclusions

Together, our results suggest that neuroinflammation has an important pathogenic role in the 2 very different human neurodegenerative disorders of AD and PSP. The increase and distribution of microglial activation suggest that immunotherapeutic strategies may be useful in slowing the progression of both diseases.

*These authors contributed equally to this work as first authors.

†These authors contributed equally to this work as last authors.

From the Departments of Clinical Neurosciences (L.P., P.V.R., Y.T.H., P.S.J., R.J.B., T.D.F., F.I.A., J.B.R.) and Psychiatry (W.R.B.-J., R.A., A.S., E.M., L.S., J.T.O.), University of Cambridge, UK; Istituto di Bioimmagini e Fisiologia Molecolare (L.P.), Consiglio Nazionale delle Ricerche, Milano, Italy; Wolfson Brain Imaging Centre (Y.T.H., D.W., T.D.F., F.I.A.), University of Cambridge; Department of Histopathology (K.S.J.A.), Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; China-UK Centre for Cognition and Ageing Research (L.S.), Southwest University, Chongqing, China; and Medical Research Council Cognition and Brain Sciences Unit (J.B.R.), UK.

Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

The Article Processing Charge was funded by an RCUK grant for Open Access.

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Glossary

AD = Alzheimer disease; **BP_{ND}** = nondisplaceable binding potential; **CRP** = C-reactive protein; **ESR** = erythrocyte sedimentation rate; **MCI** = mild cognitive impairment; **MMSE** = Mini-Mental State Examination; **NIHR** = National Institute for Health Research; **PiB** = Pittsburgh compound B; **PSP** = progressive supranuclear palsy; **PSPRS** = Progressive Supranuclear Palsy Rating Scale; **RAVLT** = Rey Auditory Verbal Learning Test; **ROI** = region of interest; **TSPO** = translocator protein.

There is evidence that microglia show increased activation in Alzheimer disease (AD), Parkinson disease, Huntington disease, and progressive supranuclear palsy (PSP).^{1–12} Furthermore, genetic association studies in AD reveal variations in genes that contribute to immune signaling as risk factors.¹³ This raises the possibility of immune-therapeutic strategies for prevention and disease modification.

However, key issues need to be addressed before such strategies can be applied, including the confirmation of clinico-pathologic correlations of neuroinflammation and the establishment of the potential utility of biomarkers for measuring and tracking neuroinflammation in vivo. Despite the importance of neuroinflammation, there is still insufficient information regarding the extent and regional distribution of microglial activation in patients with neurodegenerative conditions, and their association with clinical markers of disease severity or their relationship to systemic inflammatory markers.

[¹¹C]PK11195 is a well-established PET marker of in vivo microglial activation,^{1,2,6–8,10,14} although microglial activation represents only part of the complex cascade of events in neuroinflammation.¹⁵ Here, we assessed the magnitude and patterns of [¹¹C]PK11195 binding in 2 very different neurodegenerative entities, AD and PSP, characterized by distinct anatomical distributions of pathology. The value of this comparison does not lie in the differential diagnosis between these clinically diverse entities but rather in establishing the distribution of neuroinflammation in 2 distinct tauopathies. We tested whether [¹¹C]PK11195 binding relates to the distinctive distributions of pathology in typical amnesic AD and PSP–Richardson syndrome, and whether [¹¹C]PK11195 binding relates to different measures of clinical severity in AD and PSP.

Methods

Participants

The current study was conducted within the context of the NIMROD (Neuroimaging of Inflammation in Memory and Related Other Disorders) Study.¹⁶ We recruited 16 PSP patients with probable PSP by the 1996 Movement Disorder Society criteria (representing a “classic phenotype,” which is sometimes referred to as Richardson syndrome), but all patients also met 2017 revised criteria for probable PSP–Richardson syndrome^{17,18}; 9 patients met diagnostic criteria for probable AD¹⁹ (typical amnesic phenotype, without

biomarkers) and 7 patients had amnesic mild cognitive impairment (MCI). The patients with amnesic MCI had (1) a Mini-Mental State Examination (MMSE) score of >24/30, (2) memory impairment at least 1.5 SDs below that expected for age and education,²⁰ and (3) biomarker evidence of amyloid pathology (positive Pittsburgh compound B [PiB]-PET scan) (MCI+). Thirteen age-, sex-, and education-matched healthy controls with no history of major psychiatric or neurologic illnesses, head injury, or any other significant medical comorbidity were also recruited. All participants were older than 50 years, had sufficient proficiency in English for cognitive testing, did not have any acute infectious or symptomatic systemic inflammatory disorder (e.g., lupus, rheumatoid arthritis, Crohn disease, polymyalgia rheumatica), and had no contraindications to MRI. Patients were identified from the specialist clinics at the Cambridge University Hospitals NHS Trust and the Dementias and Neurodegenerative Diseases Research Network, while healthy controls were recruited via the Dementias and Neurodegenerative Diseases Research Network, which is part of the National Institute for Health Research (NIHR) Clinical Research Network (nihr.ac.uk/nihr-in-your-area/dementias-and-neurodegeneration/).

Standard protocol approvals, registrations, and patient consents

All participants had mental capacity, and we obtained informed written consent from patients (as principal participants) and patients’ designated informants (for providing informant information) in accordance with the Declaration of Helsinki. The study was approved by the local ethics committee.

Clinical, cognitive, and blood assessment

Participants’ assessment included clinical indices of disease severity, such as Rey Auditory Verbal Learning Test (RAVLT) in AD/MCI+ patients and Progressive Supranuclear Palsy Rating Scale (PSPRS) in patients with PSP.²¹ Demographic measures and neuropsychological tests (i.e., MMSE and Addenbrooke’s Cognitive Examination–Revised) as well as a blood sample to assess the levels of 3 basic peripheral markers of inflammation (i.e., C-reactive protein [CRP], erythrocyte sedimentation rate [ESR], and white blood cell count) were also obtained from all participants. The CRP, ESR, and white blood cell biomarkers were included on the basis that peripheral inflammation may facilitate the development of neuroinflammation and neurodegeneration,^{22–24} and such peripheral markers might augment the monitoring of immunotherapeutic trials if related to central inflammation.

Neuroimaging assessment

All participants underwent MRI on a 3T Siemens Magnetom Tim Trio or Verio scanner (medical.siemens.com) using a magnetization-prepared rapid-acquisition gradient echo T1-weighted sequence. The T1-weighted sequence (repetition time = 2,300 milliseconds, echo time = 2.98 milliseconds, field of view = $240 \times 256 \text{ mm}^2$, 176 slices of 1-mm thickness, flip angle = 9°) was used to facilitate tissue class segmentation (gray and white matter, together with CSF) and to allow nonrigid registration of standard space regions of interest (ROIs) to subject MRI space (using a modified version of the Hammers atlas, which included the midbrain, pons, cerebellar gray matter, and dentate nucleus of the cerebellum ROIs). Each T1 image was nonrigidly registered to the ICBM2009a template brain using ANTS (picsl.upenn.edu/ANTS/), and the inverse transform was applied to the modified Hammers atlas (resliced from MNI152 to ICBM2009a space) to bring the ROIs to subject MRI space.

All participants underwent [^{11}C]PK11195 PET imaging for assessment of the extent and distribution of brain inflammation. [^{11}C]PK11195 and [^{11}C]PiB were produced with high radiochemical purity (>95%), with [^{11}C]PiB having a specific activity >150 GBq/ μmol at the end of synthesis, while [^{11}C]PK11195 specific activity was around 85 GBq/ μmol at the end of synthesis. PET scanning was performed with a GE Advance PET scanner (GE Healthcare, Waukesha, WI) and a GE Discovery 690 PET/CT, with attenuation correction provided by a 15-minute $^{68}\text{Ge}/^{68}\text{Ga}$ transmission scan and a low-dose CT scan, respectively. The emission protocols were 550 MBq [^{11}C]PiB injection followed by imaging from 40 to 70 minutes post injection, and 75 minutes of dynamic imaging (55 frames) starting concurrently with a 500-MBq [^{11}C]PK11195 injection. Each emission frame was reconstructed using the PROMIS 3-dimensional filtered back projection algorithm into a 128×128 matrix 30-cm transaxial field of view, with a transaxial Hann filter cutoff at the Nyquist frequency.²⁵ Corrections were applied for randoms, dead time, normalization, scatter, attenuation, and sensitivity. Each emission image series was aligned using SPM8 to reduce the effect of patient motion during data acquisition (fil.ion.ucl.ac.uk).

The mean aligned PET image (and hence the corresponding aligned PET image series) was rigidly registered to the T1-weighted MRI. For [^{11}C]PiB, we used reference tissue ROI defined by $\geq 90\%$ on the SPM8 gray matter probability map (smoothed to PET resolution) in the superior cerebellar cortex.²⁶ For [^{11}C]PK11195, supervised cluster analysis was used to determine the reference tissue time-activity curve.²⁷ All ROI data were corrected for CSF contamination through division with the mean ROI probability (normalized to 1) of gray + white matter, using SPM8 probability maps smoothed to PET resolution. To test whether correction for CSF affected the main results, we repeated all the [^{11}C]PK11195

ROI PET analyses using data not corrected for CSF contamination (see PET statistical analyses and results sections).

[^{11}C]PiB data were quantified using standardized uptake value ratio by dividing the mean CSF-corrected radioactivity concentration in each Hammers atlas ROI by the corresponding mean CSF-corrected radioactivity concentration in the reference tissue ROI. For [^{11}C]PK11195, non-displaceable binding potential (BP_{ND}), a measure of specific binding, was determined for each ROI using a basis function implementation of the simplified reference tissue model, both with and without CSF contamination correction.²⁸ [^{11}C]PK11195 BP_{ND} maps were also generated using this basis function simplified reference tissue model approach. [^{11}C]PiB data were treated as dichotomous measures (i.e., positive or negative) and considered positive if the average standardized uptake value ratio across the cortical ROIs was >1.5.²⁹

To compare [^{11}C]PK11195 binding across groups (AD/MCI PiB+, PSP, and controls), individual ROI BP_{ND} values for [^{11}C]PK11195 were used in a repeated-measures general linear model to test for the main effect of ROI, main effect of group, and group \times ROI interaction. Age and sex were included as covariates of no interest. For the AD/MCI+ and PSP groups, we also tested Pearson correlations between regional [^{11}C]PK11195 BP_{ND} and disease severity using the RAVLT scores for AD/MCI+ patients and the PSPRS for patients with PSP. Finally, we tested for associations between neuroinflammation and peripheral markers of inflammation using Pearson correlations.

Data availability

Anonymized data will be shared by request from any qualified investigator.

Results

Clinical, cognitive, and blood findings

The patient and control groups were matched for age, sex, and education (table). Nevertheless, to account for any possible residual confounding effect associated with variability in demographic measures, age and sex were included as covariates of no interest in the general linear models of the main effect of ROI, the main effect of group, and the group \times ROI interaction. As expected, there was a significant main effect of group for cognitive measures, driven by reduced MMSE and Addenbrooke's Cognitive Examination–Revised scores in AD/MCI+ and PSP patients relative to healthy controls (table). Episodic memory, as assessed via the RAVLT (delayed recall), was significantly impaired in AD/MCI+ patients relative to controls (table). Although none of the participants included had acute inflammatory conditions (see exclusion criteria), patients with PSP displayed higher CRP levels than AD/MCI+ patients and controls, despite normal leukocyte count and ESR (table).

Table Participant details and group differences by χ^2 test, one-way analysis of variance, or independent samples *t* test

| Demographic and clinical data | AD/MCI+ (n = 16) | PSP (n = 16) | HCS (n = 13) | Group difference |
|--------------------------------------|----------------------------|---------------------------|----------------------------|---|
| Sex, M/F | 9/7 | 10/6 | 5/8 | NS (per each χ^2 test group comparison) |
| Age, y | 68.7 (\pm 8.6, 53–83) | 68.4 (\pm 5.7, 52–75) | 68.0 (\pm 5.3, 59–81) | NS (per each post hoc <i>t</i> test group comparison) |
| Education, y | 13.8 (\pm 3.1, 10–19) | 12.2 (\pm 1.9, 10–17) | 14.1 (\pm 2.7, 10–19) | NS (per each post hoc <i>t</i> test group comparison) |
| MMSE | 25.4 (\pm 3.0, 18–30) | 27.4 (\pm 1.9, 24–30) | 28.7 (\pm 1.0, 27–30) | $F = 7.60, p = 0.002$ (HCS > AD, ^a HCS > PSP, ^b PSP > AD ^b) |
| ACE-R | 77.5 (\pm 11.0, 51–89) | 82.3 (\pm 10.0, 56–95) | 91.3 (\pm 5.3, 79–99) | $F = 7.58, p = 0.002$ (HCS > AD, ^a HCS > PSP ^c) |
| RAVLT | 1.3 (\pm 1.4, 0–4) | — | 9.7 (\pm 3.2, 3–15) | $T = 8.93, p < 0.0001$ (HCS > AD ^a) |
| PSP Rating Scale | — | 40.8 (\pm 15.0, 15–74) | — | — |
| Blood markers of inflammation | | | | |
| CRP level | 2.4 (\pm 2.3, 1–9) | 4.6 (1.2, 4–8) | 1.6 (\pm 1.0, 1–4) | $F = 10.17, p = 0.0003$ (PSP > AD, ^c PSP > HCS ^a) |
| ESR | 8.5 (\pm 2.0, 2–17) | 10.1 (\pm 8.3, 1–32) | 12.1 (\pm 10.4, 4–36) | NS (per each post hoc <i>t</i> test group comparison) |
| WBC count, $\times 10^3$ | 7.1 (\pm 2.3, 5.3–10.3) | 6.7 (\pm 1.2, 4.1–8.1) | 6.9 (\pm 1.7, 4.1–10.2) | NS (per each post hoc <i>t</i> test group comparison) |

Abbreviations: ACE-R = Addenbrooke's Cognitive Examination-Revised; AD/MCI+ = Alzheimer disease/mild cognitive impairment (amyloid positive on Pittsburgh Compound B-PET scan); CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; HCS = healthy controls; MMSE = Mini-Mental State Examination; NS = not significant at $p < 0.05$ (uncorrected) by analysis of variance, post hoc *t* test, or χ^2 as appropriate; PSP = progressive supranuclear palsy; RAVLT = Rey Auditory Verbal Learning Test (delayed recall); WBC = white blood cell.

Data are mean (\pm SD, range).
Post hoc independent samples *t* tests:

^a $p < 0.005$.

^b $p < 0.05$.

^c $p < 0.01$.

Neuroimaging findings

In the repeated-measures analysis of regional binding, we found a significant main effect of ROI ($F_{2,36} = 3.8, p < 0.001$), main effect of group ($F_{2,36} = 5.7, p < 0.006$), and a group \times ROI interaction ($F_{2,70} = 2.6, p < 0.001$) (figure 1). The group and interaction effects were driven in part by higher [^{11}C] PK11195 BP_{ND} values in the AD/MCI+ group relative to both the PSP and control groups, in cortical and subcortical ROIs, including occipital, parietal, and temporal cortices, as well as in the hippocampus, amygdala, and other medial temporal lobe ROIs (figure 1). The PSP group, relative to controls, showed increased [^{11}C]PK11195 BP_{ND} in the thalamus, putamen, and pallidum (figure 1).


Repeating these analyses using ROI [^{11}C]PK11195 BP_{ND} values that were not corrected for CSF partial volume effects yielded similar results ($F_{2,36} = 2.2, p < 0.0001$ for the main effect of ROIs; $F_{2,36} = 6.1, p < 0.006$ for the main effect of group; and $F_{2,70} = 2.0, p < 0.0001$ for the group \times ROI interaction). We then tested whether regional [^{11}C] PK11195 BP_{ND} related to disease severity in each clinical group. In the AD/MCI+ group, there was a significant *negative* correlation between the RAVLT scores (delayed recall at 30 minutes) and [^{11}C]PK11195 BP_{ND} in the precuneus (figure 2A). In the PSP group, we found a significant *positive* correlation for [^{11}C]PK11195 BP_{ND} in the pallidum, mid-brain, and pons and disease severity, as assessed via the PSPRS (figure 2, B–D).

Discussion

The brain regions with the most marked abnormalities of [^{11}C]PK11195 binding in AD/MCI+ and PSP groups were those predicted from the established distribution of neurodegeneration of each disease. Specifically, patients with amnesic AD/MCI+ had evidence of increased neuroinflammation in the medial temporal lobe as well as parietal and lateral temporal cortices.^{30–33} Conversely, patients with PSP had evidence of enhanced neuroinflammation in the thalamus, pallidum, and putamen, a group of subcortical regions that have been implicated in the pathophysiology of PSP.^{34,35} The increased [^{11}C]PK11195 binding in the basal ganglia in PSP is also consistent with preliminary findings reported in a study with 4 patients with PSP.¹⁰

Our data demonstrate that the density and distribution of activated microglia in living patients with AD and PSP mirror the typical neuropathologic changes characteristic of each disorder. This could result from a causal link between neuroinflammation and neurodegeneration, although the association might also derive from the process of neurodegeneration itself. A cross-sectional and noninterventional study such as this one cannot alone provide the direction of causality. Nevertheless, the disease-specific anatomical distributions of activated microglia in AD and PSP suggest a regional association rather than a side effect of a global increased [^{11}C] PK11195 binding in response to a general inflammatory insult.

Figure 1 [^{11}C]PK11195 binding in AD, PSP, and HCs



The bar plots represent the mean values (\pm SE) of the [^{11}C]PK11195 BP_{ND} in each region of interest for the participant groups: AD and MCI+, PSP, and HCs. The [^{11}C]PK11195 BP_{ND} data reported here are corrected for CSF contamination. See the results section for statistics related to CSF-corrected and uncorrected data. Post hoc *t* tests: **p* < 0.05, ***p* < 0.01, ****p* < 0.005. AD = Alzheimer disease; BP_{ND} = nondisplaceable binding potential; HC = healthy control; MCI+ = amyloid-positive mild cognitive impairment; PSP = progressive supranuclear palsy.


Our PET data are also in keeping with previous postmortem findings,³ which demonstrated that microglia burden (as assessed via LN3 immunostaining) and interleukin 1 β and transforming growth factor β expression showed a disease-specific topological relationship with the pathologic hallmarks of AD and PSP.³ More specifically, the previous postmortem study³ found that patients with AD had significantly higher microglia density and interleukin 1 β expression in the parietal cortices compared to patients with PSP and controls, while the microglia density and cytokine expression was greater in the substantia nigra of patients with PSP relative to patients with AD and controls.³ The expression of transforming growth factor β was also increased in frontal and parietal cortices in patients with AD relative to patients with PSP or controls.³ Together with our findings, these data suggest that microglia activation and cytokine expression coexist with the pathogenic processes underlying AD and PSP and could contribute to the process of ongoing neurodegeneration.³ If so, this would warrant further investigation of immune-therapeutic strategies to modulate neuroinflammation in AD and PSP, although evidence from earlier anti-inflammatory trials in AD remains

controversial,^{36,37} and no such clinical trials have been conducted in PSP.

Our data also confirmed the hypothesis that [^{11}C]PK11195 binding correlates with disease severity in both AD/MCI+ and PSP; more specifically, with severity of episodic memory impairment as assessed via the RAVLT in AD/MCI+, and with PSP severity as measured via the PSPRS in PSP. Again, these effects were not global correlations but adhered to the functional anatomy of cognitive and motor symptoms in AD and PSP (i.e., cuneus/precuneus in relation to episodic memory deficits in AD as well as the pallidum, midbrain, and pons in relation to PSPRS in PSP).

Despite that a symptomatic acute infection and chronic extraneural inflammatory condition were exclusion criteria of our study, the patients with PSP showed higher levels of CRP in the blood, a common peripheral marker of inflammation. We acknowledge that the dysphagia and bladder dysfunction frequently experienced by patients with PSP can put them at risk of respiratory and urinary tract infections. However, the average CRP level in our PSP group was 4.6 (\pm 1.2), which is

Figure 2 [^{11}C]PK11195 binding correlates with clinical severity in AD and PSP



(A) Correlation between [^{11}C]PK11195 BP_{ND} values in the precuneus (x-axis) and RAVLT scores (y-axis) in patients with AD and MCI+ (red dots). (B–D) Correlation between [^{11}C]PK11195 BP_{ND} values in the pallidum, midbrain, and pons (x-axes) and PSP Rating Scale (y-axes) in patients with PSP. AD = Alzheimer disease; BP_{ND} = nondisplaceable binding potential; MCI+ = amyloid-positive mild cognitive impairment; PSP = progressive supranuclear palsy; RAVLT = Rey Auditory Verbal Learning Test.

well below the values expected in acute inflammatory states. In addition, the leucocyte count and ESR were both normal. The increased CRP levels in PSP might therefore reflect underlying chronic inflammatory states that sustain or even accelerate the neuroinflammation associated with PSP, in the absence of acute infection. It will be useful to replicate these findings in larger clinical cohorts and use more detailed peripheral markers of inflammation (e.g., immune-phenotyping) for characterization and classification of the immune cells in circulation in AD and PSP.

Overall, the use of [^{11}C]PK11195 PET could provide helpful information to stratify patients in future clinical trials or to track the effects of treatments targeting neuroinflammation in neurodegenerative disorders such as AD and PSP. However, to fully meet its potential toward these directions, additional properties are necessary to show for this biomarker of neuroinflammation. Specifically, although recent longitudinal studies in AD have demonstrated that changes in [^{11}C]PK11195 binding may be associated with disease progression,^{14,38} such a correlation has not been established in PSP. Neuroinflammation might be stable in symptomatic stages of PSP, as suggested by a pilot study of 2 patients with PSP.¹⁰ Furthermore, increased levels of serum neurofilament light protein have been found in both AD and PSP, and correlated with disease severity^{39–41}; hence, future studies may test whether markers of neuroinflammation are associated with neurofilament light protein levels in the serum.

Perhaps more importantly, it remains to be determined whether the putative effects of anti-inflammatory therapies can reduce the elevated [^{11}C]PK11195 binding in AD and PSP and, consequently, could help slow the progression of these disorders. This would also enable mediation analysis to test the causality between immune-reactivity and disease progression in dementia and related disorders. Furthermore, we suggest that multitracer PET studies will be useful to formally assess how neuroinflammation relates to other important molecular aspects in dementia and related disorders including, for example, studying how neuroinflammation is associated with amyloid load in AD¹⁴ as well as with tau burden in AD and PSP. A cross-sectional and single-tracer study like the present one is not able to address such interesting and open questions, although it represents the necessary first step toward achieving this goal.

Technical considerations regarding the [^{11}C]PK11195 BP_{ND} PET methods should also be considered. In particular, our main regional PET analyses used partial volume correction for CSF, which controlled for differences in CSF signal contamination within each region and across the different diagnostic groups (i.e., AD/MCI+, PSP, and control groups). Although this approach is important to reduce the potential influence of brain volume loss seen in AD/MCI+ and PSP, this MRI-guided method is subject to error because of imperfect registration of PET and MRIs, together with errors in segmentation and point spread function modeling. However, we

note that using uncorrected PET data yielded similar results in terms of the main effect of ROI, main effect of group, and group \times ROI interaction, which provides substantiation of the CSF-corrected results. The supervised cluster method for estimating [^{11}C]PK11195 BP_{ND} could also have introduced an underestimation bias, as the reference tissue may have still included specific binding of the radioligand. In any case, this may have only reduced the effect sizes without altering the risk of reporting false-positive results.

We also highlight that our data are specific to [^{11}C]PK11195 and do not inevitably generalize to second-generation translocator protein (TSPO) ligands (e.g., PBR28) or alternative tracers of neuroinflammation over and above those that bind to TSPO (e.g., COX-1, MPO, macrophage infiltration).^{42–44} Further studies should assess the utility of such novel markers for in vivo imaging of neuroinflammation, bearing in mind that the binding of second-generation TSPO tracers like PBR28 can be affected by genetic variations (i.e., the rs6971 TSPO polymorphism).⁴⁵

In conclusion, we have provided clear evidence that [^{11}C]PK11195 is a sensitive PET ligand for in vivo studies of neuroinflammation in clinical populations with AD and its prodromal stage of amnesic MCI, as well as in a non-AD tauopathy, PSP–Richardson syndrome. The brain regions that showed increased [^{11}C]PK11195 binding were those predicted from the well-established pattern of regional cortical and subcortical neurodegeneration in each disease. Our data support the further use of [^{11}C]PK11195 PET to study microglia activation in neurodegenerative disorders and in clinical trials that aim to modulate neuroinflammation in neurodegenerative disease.

Author contributions

L.P.: conception and design of the study, acquisition and analysis of data, drafting the manuscript and figures. P.V.R.: conception and design of the study, acquisition of data. Y.T.H.: acquisition and analysis of data, drafting of the manuscript. K.S.J.A.: acquisition and analysis of data, drafting of the manuscript. W.R.B.-J.: acquisition of data, drafting the manuscript. D.W.: analysis of data. P.S.J.: analysis of data, drafting the manuscript and figures. R.A.: acquisition of data, drafting the manuscript. R.J.B.: analysis of data, drafting the manuscript. A.S.: drafting the manuscript. E.M.: analysis of data. L.S.: analysis of data. T.D.F.: acquisition and analysis of data, drafting the manuscript. F.I.A.: conception and design of the study, obtaining funding. J.T.O.: conception and design of the study, obtaining funding, drafting the manuscript. J.B.R.: conception and design of the study, obtaining funding, drafting the manuscript and figures.

Study funding

This study was funded by the National Institute for Health Research Cambridge Biomedical Research Centre and Biomedical Research Unit in Dementia (NIHR, RG64473), the PSP Association, the Wellcome Trust (JBR 103838), and the Medical Research Council (MC-A060-5PQ30 and

MR/P01271X/1). Dr. Li Su is supported by Alzheimer's Research UK.

Disclosure

L. Passamonti, P. Vázquez Rodríguez, Y. Hong, K. Allinson, R. Bevan-Jones, D. Williamson, P. Jones, R. Arnold, R. Borchert, A. Surendranathan, E. Mak, L. Su, and T. Fryer report no disclosures relevant to the manuscript. F. Aigbirhio has served as review editor for *Journal of Labelled Compounds and Radiopharmaceuticals*, received academic grant support from GE Healthcare, and served as a consultant for Avid and Cantabio, all for matters not related to the current study. J. O'Brien has served as deputy editor of *International Psychogeriatrics*, received grant support from Avid (Lilly), and served as a consultant for Avid and GE Healthcare, all for matters not related to the current study. J. Rowe serves as editor to *Brain*, has been a consultant for Asceneuron and Syncona, and has received academic grant funding from AZ-MedImmune, Janssen, and Lilly, unrelated to this study. Go to Neurology.org/N for full disclosures.

Received November 13, 2017. Accepted in final form March 13, 2018.

References

1. Edison P, Archer HA, Gerhard A, et al. Microglia, amyloid, and cognition in Alzheimer's disease: an [^{11}C](R)PK11195-PET and [^{11}C]PIB-PET study. *Neurobiol Dis* 2008;32:412–419.
2. Fan Z, Aman Y, Ahmed I, et al. Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia. *Alzheimers Dement* 2015;11:608–621.e7.
3. Fernandez-Botran R, Ahmed Z, Crespo FA, et al. Cytokine expression and microglial activation in progressive supranuclear palsy. *Parkinsonism Relat Disord* 2011;17:683–688.
4. Schuitmaker A, Kropholler MA, Boellaard R, et al. Microglial activation in Alzheimer's disease: an (R)-[(1)(11C)]PK11195 positron emission tomography study. *Neurobiol Aging* 2013;34:128–136.
5. Stefaniak J, O'Brien J. Imaging of neuroinflammation in dementia: a review. *J Neurol Neurosurg Psychiatry* 2016;87:21–28.
6. Gerhard A, Pavese N, Hotton G, et al. In vivo imaging of microglial activation with [^{11}C](R)-PK11195 PET in idiopathic Parkinson's disease. *Neurobiol Dis* 2006;21:404–412.
7. Edison P, Ahmed I, Fan Z, et al. Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia. *Neuropsychopharmacology* 2013;38:938–949.
8. Cagnin A, Brooks DJ, Kennedy AM, et al. In-vivo measurement of activated microglia in dementia. *Lancet* 2001;358:461–467.
9. Anderson AN, Pavese N, Edison P, et al. A systematic comparison of kinetic modelling methods generating parametric maps for [(11C)]-(R)-PK11195. *Neuroimage* 2007;36:28–37.
10. Gerhard A, Trender-Gerhard I, Turkheimer F, Quinn NP, Bhatia KP, Brooks DJ. In vivo imaging of microglial activation with [^{11}C](R)-PK11195 PET in progressive supranuclear palsy. *Mov Disord* 2006;21:89–93.
11. Wiley CA, Lopresti BJ, Venneti S, et al. Carbon 11-labeled Pittsburgh compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. *Arch Neurol* 2009;66:60–67.
12. Kropholler MA, Boellaard R, van Berckel BN, et al. Evaluation of reference regions for (R)-[(11C)]PK11195 studies in Alzheimer's disease and mild cognitive impairment. *J Cereb Blood Flow Metab* 2007;27:1965–1974.
13. Villegas-Llerena C, Phillips A, Garcia-Reitboeck P, Hardy J, Pocock JM. Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease. *Curr Opin Neurobiol* 2016;36:74–81.
14. Fan Z, Okello AA, Brooks DJ, Edison P. Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer's disease. *Brain* 2015;138:3685–3698.
15. Agostinho P, Cunha RA, Oliveira C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. *Curr Pharm Des* 2010;16:2766–2778.
16. Bevan-Jones WR, Surendranathan A, Passamonti L, et al. Neuroimaging of Inflammation in Memory and Related Other Disorders (NIMROD) study protocol: a deep phenotyping cohort study of the role of brain inflammation in dementia, depression and other neurological illnesses. *BMJ Open* 2017;7:e013187.
17. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. *Neurology* 1996;47:1–9.

18. Hoglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. *Mov Disord* 2017;32:853–864.
19. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging–Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* 2011;7:263–269.
20. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. *Arch Neurol* 1999;56:303–308.
21. Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. *Brain* 2007;130:1552–1565.
22. Perry VH. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. *Brain Behav Immun* 2004;18:407–413.
23. Bonotis K, Krikki E, Holeva V, Aggouridaki C, Costa V, Baloyannis S. Systemic immune aberrations in Alzheimer's disease patients. *J Neuroimmunol* 2008;193:183–187.
24. Holmes C, El-Okl M, Williams AL, Cunningham C, Wilcockson D, Perry VH. Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease. *J Neurol Neurosurg Psychiatry* 2003;74:788–789.
25. Kinahan PE, Rogers JG. Analytic 3D image reconstruction using all detected events. *IEEE Trans Nucl Sci* 1989;36:964–968.
26. Schuitmaker A, van Berckel BN, Kropholler MA, et al. SPM analysis of parametric (R)-[11C]PK11195 binding images: plasma input versus reference tissue parametric methods. *Neuroimage* 2007;35:1473–1479.
27. Turkheimer FE, Edison P, Pavese N, et al. Reference and target region modeling of [11C]-(R)-PK11195 brain studies. *J Nucl Med* 2007;48:158–167.
28. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. *Neuroimage* 1997;6:279–287.
29. Hatashita S, Yamasaki H. Clinically different stages of Alzheimer's disease associated by amyloid deposition with [11C]-PIB PET imaging. *J Alzheimers Dis* 2010;21:995–1003.
30. Braak H, Alafuzoff I, Arzberger T, Kretschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. *Acta Neuropathol* 2006;112:389–404.
31. Schwarz AJ, Yu P, Miller BB, et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. *Brain* 2016;139:1539–1550.
32. Schöll M, Lockhart SN, Schonhaut DR, et al. PET imaging of tau deposition in the aging human brain. *Neuron* 2016;89:971–982.
33. Ossenkoppele R, Schonhaut DR, Baker SL, et al. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. *Ann Neurol* 2015;77:338–342.
34. Hauw JJ, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). *Neurology* 1994;44:2015–2019.
35. Litvan I, Hauw JJ, Bartko JJ, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. *J Neuropathol Exp Neurol* 1996;55:97–105.
36. Group AR, Martin BK, Szekeley C, et al. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. *Arch Neurol* 2008;65:896–905.
37. ADAPT Research Group, Lyketsos CG, Breitner JC, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. *Neurology* 2007;68:1800–1808.
38. Kreisl WC, Lyoo CH, Liow JS, et al. (11)C-PBR28 binding to translocator protein increases with progression of Alzheimer's disease. *Neurobiol Aging* 2016;44:53–61.
39. Rojas JC, Bang J, Lobach IV, et al. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. *Neurology* 2018;90:e273–e281.
40. Jabbari E, Zetterberg H, Morris HR. Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers. *J Neurol Neurosurg Psychiatry* 2017;88:883–888.
41. Hampel H, Toschi N, Baldacci F, et al. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ1–42, total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40. *Alzheimers Dement Epub* 2018 Jan 9.
42. Hamelin L, Lagarde J, Dorothee G, et al. Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging. *Brain* 2016;139:1252–1264.
43. Yokokura M, Terada T, Bunai T, et al. Depiction of microglial activation in aging and dementia: positron emission tomography with [11C]DPA713 versus [11C](R)PK11195. *J Cereb Blood Flow Metab* 2017;37:877–889.
44. Suridjan I, Pollock BG, Verhoeff NP, et al. In-vivo imaging of grey and white matter neuroinflammation in Alzheimer's disease: a positron emission tomography study with a novel radioligand, [18F]-FEPPA. *Mol Psychiatry* 2015;20:1579–1587.
45. Owen DR, Yeo AJ, Gunn RN, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. *J Cereb Blood Flow Metab* 2012;32:1–5.

Neurology[®]

[¹¹C]PK11195 binding in Alzheimer disease and progressive supranuclear palsy

Luca Passamonti, Patricia Vázquez Rodríguez, Young T. Hong, et al.

Neurology published online April 27, 2018

DOI 10.1212/WNL.0000000000005610

This information is current as of April 27, 2018

| | |
|---|--|
| Updated Information & Services | including high resolution figures, can be found at: http://n.neurology.org/content/early/2018/04/27/WNL.0000000000005610.full.html |
| Subspecialty Collections | This article, along with others on similar topics, appears in the following collection(s): Alzheimer's disease http://n.neurology.org/cgi/collection/alzheimers_disease PET http://n.neurology.org/cgi/collection/pet Progressive supranuclear palsy http://n.neurology.org/cgi/collection/progressive_supranuclear_palsy |
| Permissions & Licensing | Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://n.neurology.org/misc/about.xhtml#permissions |
| Reprints | Information about ordering reprints can be found online: http://n.neurology.org/misc/addir.xhtml#reprintsus |

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

